Shares of electroCore, Inc. (NASDAQ:ECOR – Get Free Report) have been given a consensus rating of “Hold” by the five brokerages that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $22.00.
A number of research firms have recently weighed in on ECOR. Brookline Capital Acquisition raised shares of electroCore to a “strong-buy” rating in a research report on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of electroCore in a research note on Monday, December 29th. HC Wainwright reduced their price objective on electroCore from $25.00 to $18.00 and set a “buy” rating for the company in a report on Monday, January 26th. Finally, Zacks Research downgraded electroCore from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 28th.
Read Our Latest Stock Analysis on ECOR
Institutional Investors Weigh In On electroCore
electroCore Trading Down 8.9%
NASDAQ:ECOR opened at $6.85 on Monday. The stock has a market capitalization of $54.80 million, a price-to-earnings ratio of -4.01 and a beta of 0.48. The firm has a fifty day simple moving average of $6.29 and a two-hundred day simple moving average of $5.48. electroCore has a 12 month low of $4.16 and a 12 month high of $14.61.
About electroCore
electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.
The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.
Further Reading
- Five stocks we like better than electroCore
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
